Zusammenfassung
Botulinum-Toxin (BT) hat in den letzten Jahren einen breiten Einsatz in der Neurologie und in anderen medizinischen Fächern gefunden. Bei einigen Patienten kommt es jedoch zum Auftreten von Antikörpern gegen BT (BTAK) mit vollständigem Wirkungsverlust der BT-Therapie (AKTV). Risikofaktoren für ein AKTV sind die Höhe der BT-Einzeldosis und die Länge des Interinjektionsintervals. Die Behandlungsdauer, die BT-Kumulativdosis und das Alter und das Geschlecht des Patienten stellen keine Risikofaktoren dar. Das Abwarten eines spontanen BTAK-Abfalls ist für eine fortgesetzte BT-Therapie nicht praktikabel, da die hierfür notwendigen Zeiträume zu lang sind. Es bietet jedoch die Möglichkeit, eine BT-Therapie mit modifizierten Parametern und mit neuen BT-Präparationen mit niedrigerer Antigenität erneut zu initiieren. Eine Erhöhung der BT-Dosis kann bei niedrigen BTAK-Titern und bei einem mäßig reduzierten BT-Ansprechen der Zielmuskeln hilfreich sein. Die Verwendung alternativer BT-Typ-A-Präparate führt nicht zu einer Überwindung des AKTV. Alternative BT-Typen, wie BT Typ B und BT Typ F, sind zunächst bei AKTV wirksam, lösen jedoch bei den meisten Patienten bereits nach wenigen Gaben Antikörperbildungen gegen die alternativen BT-Typen aus. Dabei ist die Gabe von BT Typ B mit zum Teil heftigen systemischen anticholinergen Nebenwirkungen verbunden.
Summary
Botulinum toxin (BT) has been used with great success in a large number of medical specialities. In some patients, however, formation of antibodies against BT (BTAB), with therapy failure (ABTF) occurs. Risk factors for ABTF are the amount of BT given at each injection series and the duration of the intervals between injection series. Treatment time and cumulative BT dose as well as patient age and gender are not independent risk factors. BTAB titres drop spontaneously after cessation of BT therapy, but latencies are too long to be compatible with a clinically effective therapy. Once these titres have dropped, BT therapy can be restarted using improved parameters and improved BT preparations with lower antigenicity. Increasing the BT dosage can be successful for overcoming ABTF when BTAB titres are low and target muscle responses are only moderately reduced. The use of alternative BT type A preparations fails to overcome ABTF. Alternative BT types such as types B and F are initially successful in ABTF but stimulate the formation of antibodies against the alternative BT types after few applications. When type B is used, substantial systemic anticholinergic side effects can occur. Prevention of BTAB formation is of paramount importance. Risk factors for BTAB formation have to be taken into account when planning BT therapy. The most interesting perspective, however, seems to be the development of new BT preparations with improved specific potency and reduced antigenicity.
Literatur
Biglan AW, Gonnering R, Lockhart LB, Rabin B, Fuerste FH (1986) Absence of antibody production in patients treated with botulinum A toxin. Am J Ophthalmol 101:232–235
Boroojerdi B, Ferbert A, Schwarz M, Herath H, Noth J (1998) Botulinum toxin treatment of synkinesia and hyperlacrimation after facial palsy. J Neurol Neurosurg Psychiatry 65:111–114
Braune C, Erbguth F, Birklein F (2001) Dose thresholds and duration of the local anhidrotic effect of botulinum toxin injections: Measured by sudometry. Br J Dermatol 144:111–117
Brin MF, Lew MF, Adler CH et al. (1999) Safety and efficacy of NeuroBloc® (botulinum toxin type B) in type A-resistant cervical dystonia. Neurology 53:1431–438
Bushara KO (1997) Sialorrhea in amyotrophic lateral sclerosis: a hypothesis of a new treatment-botulinum toxin A injections of the parotid glands. Med Hypotheses 48:337–339
Bushara KO, Park DM (1994) Botulinum toxin and sweating. J Neurol Neurosurg Psychiatry 57:1437–1438
Chen R, Karp BI, Hallett M (1998) Botulinum toxin type F for treatment of dystonia: Long-term experience. Neurology 51:1494–1506
DasGupta BR (1994) Structures of botulinum neurotoxin, its functional domains, and perspectives on the crystalline type A toxin. In: Jankovic J, Hallett M (eds) Therapy with botulinum toxin. Marcel Dekker, New York, pp 15–40
Dressler D (1997) Botulinum toxin therapy failure: Causes, evaluation procedures and management strategies. Eur J Neurol 4 [Suppl 2]:67–70
Dressler D (2000) Botulinum Toxin Therapy. Thieme, Stuttgart
Dressler D (2000) Complete secondary botulinum toxin therapy failure in blepharospasm. J Neurol 247:809–810
Dressler D (2002) Clinical features of secondary failure of botulinum toxin therapy. Eur Neurol 48:26–29
Dressler D, Benecke R (2003) Autonomic side effects of botulinum toxin type B treatment of cervical dystonia and hyperhidrosis. Eur Neurol 49:34–38
Dressler D, Benecke R, Bigalke H (2003) Botulinum toxin type B (NeuroBloc®) in patients with botulinum toxin type A antibody-induced therapy failure. J Neurol 250:967–969
Dressler D, Bigalke H (2002) Botulinum toxin antibody titres after cessation of botulinum toxin therapy. Mov Disord 17:170–173
Dressler D, Dirnberger G (2000) Botulinum toxin therapy: Risk factors for therapy failure. Mov Disord 15 [Suppl 2]:51
Dressler D, Dirnberger G (2001) Botulinum toxin antibody testing: Comparison between an immunoprecipitation assay and the mouse diaphragm assay. Eur Neurol 45:257–260
Dressler D, Dirnberger G, Bhatia K, Quinn NP, Irmer A, Bigalke H, Marsden CD (2000) Botulinum toxin antibody testing: Comparison between the mouse diaphragm bioassay and the mouse lethality bioassay. Mov Disord 15:973–976
Dressler D, Lange M, Bigalke H (2003) Detecting neutralising antibodies against botulinum toxin type B with a mouse diaphragm assay. Ann Neurol (in press)
Dressler D, Muenchau A, Bhatia KP, Quinn NP, Bigalke H (2002) Antibody induced botulinum toxin therapy failure: Can it be overcome by increased botulinum toxin doses? Eur Neurol 47:118–121
Dressler D, Rothwell JC (2000) Electromyographic quantification of the paralysing effect of botulinum toxin. Eur Neurol 43:13–16
Dressler D, Rothwell JC Bigalke H (2000) The sternocleidomastoid test: An in-vivo assay to investigate botulinum toxin antibody formation in man. J Neurol 247:630–632
Dressler D, Zettl U, Benecke R, Bigalke H (2000) Can intravenous immunoglobulin improve antibody-mediated botulinum toxin therapy failure? Mov Disord 15:1279–1281
Duane DD, Monroe J, Morris RE (2000) Mycophenolate in the prevention of recurrent neutralizing botulinum toxin A antibodies in cervical dystonia. Mov Disord 15:365–366
Frueh BR, Felt DP, Wojno TH, Musch DC (1984) Treatment of blepharospasm with botulinum toxin. A preliminary report. Arch Ophthalmol 102:1464–1468
Gobel H, Heinze A, Heinze-Kuhn K, Austermann K (2001) Botulinum toxin A in the treatment of headache syndromes and pericranial pain syndromes. Pain 91:195–199
Goeschel H, Wohlfahrt K, Frevert J, Dengler R, Bigalke H (1997) Botulinum A toxin: Neutralizing and nonneutralizing antibodies—therapeutic consequences. Exp Neurol 147:96–102
Gonnering RS (1988) Negative antibody response to long-term treatment of facial spasm with botulinum toxin. Am J Ophthalmol 105:313–315
Greene P, Fahn S, Diamond B (1994) Development of resistance to botulinum toxin type A in patients with torticollis. Mov Disord 9:213–217
Hanna PA, Jankovic J (1998) Mouse bioassay versus Western blot assay for botulinum toxin antibodies: Correlation with clinical response. Neurology 50:1624–1629
Hanna PA, Jankovic J, Vincent A (1998) Comparison of mouse bioassay and immunoprecipitation assay for botulinum toxin antibodies. J Neurol Neurosurg Psychiat 66:612–616 (Correction: J Neurol Neurosurg Psychiat 67:133)
Houser MK, Sheean GL, Lees AJ (1998) Further studies using higher doses of botulinum toxin type F for torticollis resistant to botulinum toxin type A. J Neurol Neurosurg Psychiatry 64:577–580
Jankovic J, Ahsan J, Vuong KD (2002) Comparison of immunogenicity of old versus current BOTOX in cervical dystonia. Naunyn Schmiedebergs Arch Pharmacol 365 [Suppl 2]: R25
Jankovic J, Hallett M (eds) (1994) Therapy with botulinum toxin. Marcel Dekker, New York
Jankovic J, Schwartz K (1995) Response and immunoresistance to botulinum toxin injections. Neurology 45:1743–1746
Kessler KR, Benecke R (1997) The EBD test—a clinical test for the detection of antibodies to botulinum toxin type A. Mov Disord 2:95–99
Kessler KR, Skutta M, Benecke R (1999) Long-term treatment of cervical dystonia with botulinum toxin A: efficacy, safety, and antibody frequency. German Dystonia Study Group. J Neurol 246:265–274
Naumann M, Toyka KV, Mansouri Taleghani B, Ahmadpour J, Reiners K, Bigalke H (1998) Depletion of neutralising antibodies resensitises a secondary non-responder to botulinum A neurotoxin. J Neurol Neurosurg Psychiatry 65:924–927
Notermans S, Nagel J (2000) Assays for botulinum and tetanus toxins. In: Simpson LL (ed). Botulinum neurotoxin and tetanus toxin. San Diego: Academic Press 319–331
Palace J, Nairne A, Hyman N, Doherty TV, Vincent A (1998) A radioimmuno-precipitation assay for antibodies to botulinum A. Neurology 50:1463–1466
Pearce LB, Borodic GE, First ER, MacCallum RD (1994) Measurement of botulinum toxin activity: Evaluation of the lethality assay. Toxicol Appl Pharmacol 128:69–77
Sankhla C, Jankovic J, Duane D (1998) Variability of the immunologic and clinical response in dystonic patients immunoresistant to botulinum toxin injections. Mov Disord 13:150–154
Siegel LS (1988) Human immune response to botulinum pentavalent (ABCDE) toxoid determined by a neutralization test and by an enzyme-linked immunosorbent assay. J Clin Microbiol 26:2351–2356
Wittstock M, Benecke R, Bigalke H, Dressler D (2001) Quantitative antibody status of patients with continued sensitivity to long-term botulinum toxin therapy. Neurology 56 [Suppl 3]:A347
Zuber M, Sebald M, Bathien N, de Recondo J, Rondot P (1993) Botulinum antibodies in dystonic patients treated with type A botulinum toxin: Frequency and significance. Neurology 43:1715–1718
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Dressler, D. Antikörpervermitteltes Versagen der Botulinum-Toxin-Therapie. Nervenarzt 74, 1098–1104 (2003). https://doi.org/10.1007/s00115-003-1611-5
Issue Date:
DOI: https://doi.org/10.1007/s00115-003-1611-5
Schlüsselwörter
- Botulinum-Toxin-Antikörper
- Klinisches Bild
- Behandlungsstrategien
- Therapieversagen
- Botulinum-Toxin-Therapie
- Risikofaktoren